动物用药品製剂市场－全球产业规模、份额、趋势、机会与预测：按产品、动物种类、给药途径、地区和竞争格局划分，2021-2031年

全球动物用药品製剂市场预计将从 2025 年的 17.7 亿美元成长到 2031 年的 28.6 亿美元，复合年增长率为 8.33%。

在这个专业领域，持有执照的专业人员会配製药物成分，并在已通过核准药物无法使用或不适用时，为动物生产定製药物。市场成长的主要驱动力是伴侣动物医疗化程度的提高，以及临床上对物种特异性剂型和调味剂的需求，以确保治疗依从性。这并非暂时的市场波动，而是畜牧养殖户和宠物饲主对兽医护理标准持续提升的标誌。

阻碍市场发展的一大障碍是对药品原料药监管力道的加强。这给药店带来了沉重的合规责任，并限制了某些处方药的取得。儘管面临这些监管挑战，但由于消费者在动物保健方面的持续支出，该行业的经济基础仍然稳固。根据美国宠物用品协会（APPA）的数据，2024年美国兽医保健支出和产品销售额将达398亿美元。如此庞大的支出凸显了市场的可持续性以及对个人化动物医药医疗的持续需求。

市场驱动因素

市售兽药的停产和供不应求正成为全球动物用药品配製市场的主要动力，造成亟需的治疗缺口，而这一缺口只能透过定製药物来填补。随着製药公司停止生产盈利的过时药物，并面临严重的供应链中断，兽医越来越依赖药局来确保基本治疗的持续性。随着临床需求和市售药物供应缺口的扩大，这种依赖性也不断增强。根据加拿大兽医协会 (CVMA) 2025 年 11 月发布的一份报告，加拿大兽医将发现他们之前使用的药物中有 40% 几乎无法获得，这将使配製行业从辅助服务转变为预防因生产不稳定而导致的动物健康问题的关键基础设施。

同时，宠物拥有率的上升以及人们对伴侣动物日益人性化的认知，从根本上改变了药物需求的规模和复杂性。饲主将宠物视为家庭成员，他们越来越需要先进的治疗方法和物种特异性製剂，例如经皮凝胶和调味液体，以确保遵守用药并提高宠物的生活品质。这种文化演变体现在拥有宠物的家庭数量的显着增长。根据澳洲动物医学会2025年9月发布的报告，全国73%的家庭将拥有宠物。这一人口趋势为动物保健产业提供了强劲的经济基础，硕腾公司（Zoetis）的业绩也印证了这一点。该公司在2025年11月公布的第三季销售额为24亿美元，主要得益于对伴侣动物疗法的持续需求。

市场挑战

全球动物用药品配製市场发展面临的主要障碍之一是对原料药）使用日益严格的监管。监管机构正在执行严格的指导方针，限製药剂师使用原料药​​配製药物，并强制要求优先使用FDA核准的商业产品，即使这些产品并非特定动物病情的最佳选择。这种监管立场对市场成长构成重大阻碍，迫使药局承担高昂的营运成本和行政负担以证明其合规性。因此，许多机构被迫缩减产品线，甚至完全退出兽药领域，导致客製化兽药的整体供应量下降。

这种限制性环境严重阻碍了市场应对供应链短缺的能力。例如，美国药局配药联盟 (Alliance for Pharmacy Compounding) 2024 年的一项调查发现，28% 的受访药局正在专门配製阿莫西林悬浮液，以缓解市售产品的短缺。当法规限制原材料的使用时，应对此类关键短缺所需的柔软性就会丧失。强制执行这些严格的限制会在行业内造成瓶颈，使其无法充分扩大定製药品的供应规模，以满足兽医和畜牧养殖户不断变化的需求，最终阻碍整个市场的成长。

市场趋势

随着兽医在传统药品分发监管日益严格的情况下寻求合规库存管理的方法，503B外包设施（专门为兽医诊所提供库存管理服务）的增长正在显着改变供应链。与仅限于患者特定处方笺的503A药房不同，503B设施按照联邦药品生产品质管理规范（cGMP）运营，能够生产保质期长的散装製剂，供诊所合法储存以备即时使用。这种结构性变革正在推动对设施改善的资本投资，以满足对标准化、受监管动物医药日益增长的需求。正如俄亥俄州就业局在2024年9月报导的那样，韦奇伍德俄亥俄州公司宣布投资550万美元扩建其已在FDA註册的503B外包设施，以增强其对这些重要散装製剂的生产和供给能力。

同时，透过策略併购的市场整合正在加速推进，主要企业不断吸收专业知识并拓展其地域覆盖范围。主要企业正在收购本地药局和技术平台，以确保在分散的药局市场中占据更大的份额，并优化其在兽药和人用药领域的运作。这种整合使企业能够享受规模经济效益，同时扩展其业务范围，将危险品、无菌和非无菌配製服务纳入单一组织。这一趋势在近期的几项重大交易中均有所体现。例如，根据DVM360在2024年12月报道，Greywolf Animal Health以2,250万美元收购了曼尼托巴省的Compounding Pharmacy，以加强其药房部门并拓展其在加拿大市场的服务能力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：动物用药品配製全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类别（抗感染剂、抗发炎药、荷尔蒙及其替代品、中枢神经系统药物、其他）
  • 动物种类（伴侣动物、家畜）
  • 给药途径（口服、注射、外用、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美动物用药品配製市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲动物用药品配製市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区动物用药品配製市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲动物用药品配製市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲动物用药品配製市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球动物用药品配製市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Animal Drug Compounding Market is projected to expand from USD 1.77 Billion in 2025 to USD 2.86 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.33%. This specialized sector involves licensed professionals manipulating pharmaceutical ingredients to produce customized medications for animals when approved commercial drugs are unavailable or inappropriate. The market's upward trajectory is primarily sustained by the growing medicalization of companion animals and the clinical requirement for dosage forms and flavorings tailored to specific species to guarantee treatment compliance. Rather than representing fleeting market shifts, these factors signify a lasting advancement in the veterinary care standards demanded by livestock producers and pet owners alike.

One significant obstacle hindering market progression is the heightened regulatory oversight concerning bulk drug substances, which places heavy compliance responsibilities on compounding pharmacies and restricts access to specific preparations. Despite these regulatory difficulties, the industry's economic base remains strong, supported by persistent consumer spending on animal health. Data from the American Pet Products Association indicates that expenditures on veterinary care and product sales in the United States reached $39.8 billion in 2024. This significant financial dedication highlights the market's durability and the ongoing need for personalized veterinary pharmacotherapy.

Market Driver

The discontinuation and shortage of commercial veterinary drugs act as primary catalysts for the Global Animal Drug Compounding Market by generating urgent therapeutic gaps that only customized medications can bridge. As pharmaceutical companies cease production of older, less profitable drugs or face significant supply chain obstacles, veterinarians increasingly depend on compounding pharmacies to ensure continuity of care for essential treatments. This dependency is growing as the disparity between clinical necessities and commercial availability widens. According to the Canadian Veterinary Medical Association in November 2025, veterinarians in Canada have effectively lost access to 40% of the medications formerly used for patient care, transforming the compounding sector from an auxiliary service into a vital infrastructure that prevents manufacturing instability from compromising animal health.

Concurrently, the increasing rates of pet adoption and the humanization of companion animals are fundamentally changing the scale and intricacy of pharmaceutical requirements. Owners who regard their pets as essential family members are seeking sophisticated medical treatments and species-specific formulations, such as transdermal gels or flavored liquids, to enhance adherence and quality of life. This cultural evolution is reflected in significant ownership growth, with Animal Medicines Australia reporting in September 2025 that pet ownership has risen to include 73% of households nationally. This demographic trend underpins a robust economic landscape for animal health, further demonstrated by Zoetis Inc., which reported third-quarter revenue of $2.4 billion in November 2025 due to enduring demand for companion animal therapies.

Market Challenge

The central hurdle obstructing the Global Animal Drug Compounding Market's development is the escalating regulatory scrutiny surrounding the utilization of bulk drug substances. Authorities are rigorously implementing guidelines that restrict pharmacists from compounding medications using bulk active ingredients, mandating a preference for FDA-approved commercial products even if those options are not the ideal fit for a specific animal's condition. This regulatory stance creates a significant impediment to market growth, as compounding pharmacies are forced to absorb higher operational expenses and administrative tasks to demonstrate compliance. Consequently, numerous facilities are compelled to limit their product ranges or withdraw from the animal health sector entirely, thereby diminishing the overall accessibility of customized veterinary medications.

This constrained environment significantly hampers the market's capacity to react to supply chain deficiencies. For example, the Alliance for Pharmacy Compounding reported in 2024 that 28% of surveyed compounding pharmacies prepared amoxicillin suspension explicitly to alleviate commercial shortages. When regulations restrict the use of bulk substances, they reduce the flexibility needed to manage such critical shortfalls. By enforcing these strict boundaries, the industry encounters a bottleneck where the provision of tailored medications cannot sufficiently expand to satisfy the changing requirements of veterinarians and livestock producers, ultimately stagnating the market's broader expansion.

Market Trends

The growth of 503B outsourcing facilities dedicated to office-use stock is profoundly transforming the supply chain, as veterinarians search for compliant methods to sustain inventory amidst stricter regulations on traditional compounding. In contrast to 503A pharmacies, which are limited to patient-specific prescriptions, 503B facilities function under federal Good Manufacturing Practices (cGMP), enabling the production of bulk preparations with longer shelf lives that clinics can legally stock for immediate use. This structural evolution is prompting capital investment into facility improvements to satisfy the rising demand for standardized, compliant veterinary drugs. As reported by JobsOhio in September 2024, Wedgewood Connect Ohio declared a capital investment of $5.5 million to enlarge its FDA-registered 503B outsourcing facility, thereby enhancing its capacity to manufacture and supply these essential bulk formulations.

At the same time, market consolidation driven by strategic mergers and acquisitions is gaining momentum as leading competitors absorb specialized capabilities and extend their geographic reach. Dominant firms are purchasing regional pharmacies and technology platforms to secure a greater portion of the fragmented compounding market and optimize operations across both veterinary and human sectors. This aggregation enables companies to exploit economies of scale while broadening their portfolios to encompass hazardous, sterile, and non-sterile compounding services within a single entity. This trend is illustrated by recent significant transactions; for example, DVM360 reported in December 2024 that Grey Wolf Animal Health Corp acquired the Compounding Pharmacy of Manitoba for $22.5 million to strengthen its pharmacy division and widen its service capabilities in the Canadian market.

Key Market Players

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

Report Scope

In this report, the Global Animal Drug Compounding Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Drug Compounding Market, By Product

• Anti-infective Agents
• Anti-inflammatory Agents
• Hormones & Substitutes
• CNS Agents
• Others

Animal Drug Compounding Market, By Animal Type

• Companion Animal
• Livestock Animal

Animal Drug Compounding Market, By Route of Administration

• Oral
• Injectable
• Topical
• Others

Animal Drug Compounding Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Drug Compounding Market.

Available Customizations:

Global Animal Drug Compounding Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Drug Compounding Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, Others)
  • 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
  • 5.2.3. By Route of Administration (Oral, Injectable, Topical, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Animal Drug Compounding Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Drug Compounding Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Animal Drug Compounding Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Animal Drug Compounding Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration

7. Europe Animal Drug Compounding Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Drug Compounding Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. France Animal Drug Compounding Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. United Kingdom Animal Drug Compounding Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. Italy Animal Drug Compounding Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Animal Drug Compounding Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Animal Drug Compounding Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Drug Compounding Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Animal Drug Compounding Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Animal Drug Compounding Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Animal Drug Compounding Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Animal Drug Compounding Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Animal Drug Compounding Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Drug Compounding Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. UAE Animal Drug Compounding Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. South Africa Animal Drug Compounding Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration

10. South America Animal Drug Compounding Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Drug Compounding Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Colombia Animal Drug Compounding Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. Argentina Animal Drug Compounding Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Drug Compounding Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Wedgewood Village Pharmacy, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Vimian Group AB
• 15.3. Pharmaca Health Intelligence Ltd
• 15.4. Akina Animal Health
• 15.5. Triangle Compounding Pharmacy
• 15.6. Davis Islands Pharmacy & Compounding Lab
• 15.7. Custom Med Compounding Pharmacy
• 15.8. Central Compounding Center South
• 15.9. Wellness Compounding Pharmacy of Cary
• 15.10. Millers Pharmacy

16. Strategic Recommendations

17. About Us & Disclaimer